EXEL vs. HALO, NBIX, RGEN, BCRX, CRSP, PCVX, DNLI, ABCM, DNA, and VIR
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), Repligen (RGEN), BioCryst Pharmaceuticals (BCRX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Denali Therapeutics (DNLI), Abcam (ABCM), Ginkgo Bioworks (DNA), and Vir Biotechnology (VIR). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis vs.
Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.
In the previous week, Exelixis had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Exelixis' average media sentiment score of 1.01 beat Halozyme Therapeutics' score of 0.34 indicating that Exelixis is being referred to more favorably in the news media.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 68.99% of users gave Halozyme Therapeutics an outperform vote while only 68.62% of users gave Exelixis an outperform vote.
Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a net margin of 25.76% compared to Exelixis' net margin of 9.24%. Halozyme Therapeutics' return on equity of 184.32% beat Exelixis' return on equity.
Halozyme Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
96.3% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 84.7% of Exelixis shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Halozyme Therapeutics presently has a consensus price target of $54.78, suggesting a potential upside of 60.97%. Exelixis has a consensus price target of $25.33, suggesting a potential upside of 31.67%. Given Halozyme Therapeutics' higher probable upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.
Summary
Halozyme Therapeutics beats Exelixis on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Exelixis Competitors List
Related Companies and Tools